32173
document
Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia . We evaluated the effects of extended-release alfuzosin HCl 10 mg once daily ( q.d . ) on sexual function in men with lower urinary tract symptoms associated with benign prostatic hyperplasia ( BPH ) . In a randomized , double-blind , placebo-controlled study of men aged > or = 50 years , after a 28-day placebo run-in period , patients were randomized to receive alfuzosin 10 mg q.d . or matching placebo for 28 days . The mean change from baseline ( day 1 ) in sexual function on day 29 was assessed using the Danish Prostate Symptom Score Sex ( DAN-PSSsex ) questionnaire . A total of 372 patients were randomized to receive alfuzosin ( n=186 ) or placebo ( n=186 ) , with 355 completing the study . At baseline , 64 % of the patients reported erectile dysfunction ( ED ) and 63 % reported ejaculatory dysfunction ( EjD ) . For the 320 patients who completed the DAN-PSSsex , alfuzosin treatment was associated with a significant improvement in the mean change from baseline in erectile function on day 29 compared with placebo ( P=0.02 ) . No significant difference was observed between the two treatment groups in the mean change from baseline in ejaculatory function on day 29 . For patients with ED at baseline , a marginal improvement in erectile function was demonstrated with alfuzosin treatment ( P=0.09 vs placebo ) . For patients with EjD at baseline , the mean change from baseline in ejaculatory function with alfuzosin was comparable to that with placebo . Dizziness was the most common adverse event with alfuzosin treatment ( 5 vs 0 % with placebo ) , with other adverse events reported with comparable frequency in both treatment groups . After 1 month of treatment , alfuzosin 10 mg q.d . significantly improved erectile function in men with lower urinary tract symptoms/ benign prostatic hypertrophy and had no adverse effect on ejaculatory function .
32174
Intervention_Pharmacological
alfuzosin
32175
Intervention_Pharmacological
alfuzosin
32176
Intervention_Control
placebo-controlled
32177
Intervention_Pharmacological
alfuzosin
32178
Intervention_Control
or matching placebo
32179
Intervention_Pharmacological
alfuzosin
32180
Intervention_Control
placebo
32181
Outcome_Physical
sexual function
32182
Outcome_Physical
sexual function
32183
Outcome_Physical
erectile dysfunction ( ED )
32184
Outcome_Physical
ejaculatory dysfunction ( EjD )
32185
Outcome_Physical
mean change from baseline in erectile function
32186
Outcome_Physical
mean change from baseline in ejaculatory function
32187
Outcome_Physical
erectile function
32188
Outcome_Physical
ejaculatory function
32189
Outcome_Adverse-effects
Dizziness
32190
Outcome_Physical
erectile function
32191
Participant_Sex
men
32192
Participant_Condition
symptomatic benign prostatic hyperplasia
32193
Participant_Sex
men
32194
Participant_Condition
lower urinary tract symptoms
32195
Participant_Condition
benign prostatic hyperplasia ( BPH )
32196
Participant_Sex
men
32197
Participant_Age
aged > or = 50 years
32198
Participant_Sample-size
372
32199
Participant_Condition
erectile dysfunction ( ED )
32200
Participant_Condition
ejaculatory dysfunction ( EjD )